MapLight Therapeutics stock tumbles 40% on trial results By Investing.com
MapLight Therapeutics (NASDAQ:MPLT) shares fell about 40% after topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. The 210/3 mg twice-daily dose met the primary PANSS endpoint at Week 5 versus placebo, while the 330/6 mg once-daily dose did not. The twice-daily arm also showed significant secondary endpoints; safety was generally tolerable. The company plans an FDA End-of-Phase 2 meeting.
How this was made
The 30-second read
Why it matters
The primary endpoint failure for the once-daily dose is a direct negative for that regimen’s development prospects, while statistical success for the twice-daily dose and plans for FDA engagement keep a credible development pathway.
Market read
A dosing-specific primary endpoint miss plus a dosing-specific primary endpoint win creates a re-rating of MPLT’s lead program and near-term FDA/Phase 3 expectations.
What to watch
Traders may over-discount the once-daily failure without fully weighting the planned End-of-Phase 2 FDA alignment and the confirmatory trial design focused on the successful twice-daily regimen.
Background
MapLight Therapeutics announced topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, comparing once-daily versus twice-daily dosing.
Ticker impact
MapLight Therapeutics shares fell 40% after Phase 2 ZEPHYR topline results showed the once-daily dose missed the primary endpoint in schizophrenia.
Further volatility likely as traders reprice probability of Phase 3 success and the FDA path after the End-of-Phase 2 meeting.
The article reports a clear primary-endpoint miss for one dosing regimen, while also noting statistical success for the twice-daily regimen and plans for FDA discussion, which directly affects development risk and valuation.
Market effects
Reinforces that schizophrenia CNS trials can hinge on dosing frequency and exposure, potentially increasing selectivity for future CNS readouts.
Limited, primarily affects US small/mid-cap biotech sentiment.
Low, as the catalyst is company-specific clinical trial data.
Counterpoint
The twice-daily arm met the primary endpoint and showed significant secondary and cognitive benefits, which could preserve a viable path forward despite the once-daily miss.
Key entities
- companyMapLight Therapeutics, Inc.
NASDAQ-listed biotech whose Phase 2 ZEPHYR topline results drove a sharp share decline.
- drug_candidateML-007C-MA
Investigational schizophrenia treatment evaluated in the Phase 2 ZEPHYR trial.
- clinical_trialPhase 2 ZEPHYR trial
Trial whose topline results showed success for twice-daily dosing and failure for once-daily dosing on the primary endpoint.
- regulatory_milestoneFDA End-of-Phase 2 meeting
Planned discussion to define the path forward and Phase 3 trial design.
